miR-210 Is a Prognostic Marker in Clear Cell Renal Cell Carcinoma

Slides:

Advertisements

Similar presentations

Measurement of Relative Copy Number of CDKN2A/ARF and CDKN2B in Bladder Cancer by Real-Time Quantitative PCR and Multiplex Ligation-Dependent Probe Amplification.

Advertisements

Design and Multiseries Validation of a Web-Based Gene Expression Assay for Predicting Breast Cancer Recurrence and Patient Survival Ryan K. Van Laar The.

Development and Clinical Validation of a Real-Time PCR Assay for PITX2 DNA Methylation to Predict Prostate-Specific Antigen Recurrence in Prostate Cancer.

PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies Barbara Uhl, Heidrun Gevensleben, Yuri Tolkach,

Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression Weixin Wang, Meghan Corrigan-Cummins,

Volume 15, Pages (February 2017)

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Factor VII-Induced MicroRNA-135a Inhibits Autophagy and Is Associated with Poor Prognosis in Hepatocellular Carcinoma Kuang-Tzu Huang, I-Ying Kuo, Ming-Chao.

Genes with Bimodal Expression Are Robust Diagnostic Targets that Define Distinct Subtypes of Epithelial Ovarian Cancer with Different Overall Survival

Statistical Considerations for Immunohistochemistry Panel Development after Gene Expression Profiling of Human Cancers Rebecca A. Betensky, Catherine.

A Strategy to Find Suitable Reference Genes for miRNA Quantitative PCR Analysis and Its Application to Cervical Specimens Iris Babion, Barbara C. Snoek,

Diego M. Marzese, Dave S. B. Hoon, Kelly K. Chong, Francisco E

Lunx Is a Superior Molecular Marker for Detection of Non-Small Lung Cell Cancer in Peripheral Blood Michael Mitas, Loretta Hoover, Gerard Silvestri,

Morten Andersen, Morten Grauslund, Jesper Ravn, Jens B

High Expression of PHGDH Predicts Poor Prognosis in Non–Small Cell Lung Cancer Jinhong Zhu, Jianqun Ma, Xudong Wang, Tianjiao Ma, Shu Zhang, Wei Wang,

Mark G. Erlander, Xiao-Jun Ma, Nicole C

Genome-Wide Identification and Validation of a Novel Methylation Biomarker, SDC2, for Blood-Based Detection of Colorectal Cancer TaeJeong Oh, Nayoung.

The Clinical Implications of Inconsistently Methylated Results from Glioblastoma MGMT Testing by Replicate Methylation-Specific PCR Daniel Xia, David.

False Positives in Multiplex PCR-Based Next-Generation Sequencing Have Unique Signatures Chad M. McCall, Stacy Mosier, Michele Thiess, Marija Debeljak,

Simple Detection of Telomere Fusions in Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm, and Pancreatic Cyst Fluid Tatsuo Hata, Marco Dal.

Quantitative Fluorescence in Situ Hybridization and its Ability to Predict Bladder Cancer Recurrence and Progression to Muscle-Invasive Bladder Cancer

High Expression of Lymphocyte-Activation Gene 3 (LAG3) in Chronic Lymphocytic Leukemia Cells Is Associated with Unmutated Immunoglobulin Variable Heavy.

A DNA Real-Time Quantitative PCR Method Suitable for Routine Monitoring of Low Levels of Minimal Residual Disease in Chronic Myeloid Leukemia Paul A.

Joanna Wang, Chetan Bettegowda The Journal of Molecular Diagnostics

Maxim B. Freidin, Neesa Bhudia, Eric Lim, Andrew G

Development and Clinical Validation of a Real-Time PCR Assay for PITX2 DNA Methylation to Predict Prostate-Specific Antigen Recurrence in Prostate Cancer.

Novel Molecular Method for Detection of Bovine-Specific Central Nervous System Tissues as Bovine Spongiform Encephalopathy Risk Material in Meat and Meat.

Design and Multiseries Validation of a Web-Based Gene Expression Assay for Predicting Breast Cancer Recurrence and Patient Survival Ryan K. Van Laar

An Accurate, Clinically Feasible Multi-Gene Expression Assay for Predicting Metastasis in Uveal Melanoma Michael D. Onken, Lori A. Worley, Meghan D.

Proliferating Endothelial Cells and Leukocyte Infiltration as Prognostic Markers in Colorectal Cancer Coen I.M. Baeten, Karolien Castermans, Harry F.P.

Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression Weixin Wang, Meghan Corrigan-Cummins,

Heather N. Reich, Carol Landolt-Marticorena, Paul C

Diagnostic and Prognostic Value of Metastasis Inducer S100A4 Transcripts in Plasma of Colon, Rectal, and Gastric Cancer Patients Ulrike Stein, Susen.

PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies Barbara Uhl, Heidrun Gevensleben, Yuri Tolkach,

Genomic Variation by Whole-Genome SNP Mapping Arrays Predicts Time-to-Event Outcome in Patients with Chronic Lymphocytic Leukemia Carmen D. Schweighofer,

Yuqiu Jiang, Graham Casey, Ian C

Co-Overexpression of Cyclooxygenase-2 and Microsomal Prostaglandin E Synthase-1 Adversely Affects the Postoperative Survival in Non-small Cell Lung Cancer

Identification of Combinatorial Genomic Abnormalities Associated with Prostate Cancer Early Recurrence Xiaoyu Qu, Claudio Jeldres, Lena Glaskova, Cynthia.

Kyong-Ah Yoon, Sohee Park, Sang Hee Lee, Jin Hee Kim, Jin Soo Lee

Katja Lundgren, Nicholas P

Molecular Classification of Renal Tumors by Gene Expression Profiling

Hala Faragalla, Youssef M

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Cyclin E1 Is Amplified and Overexpressed in Osteosarcoma

Kelsie L. Thu, BSc, Raj Chari, PhD, William W

Olivier Gruselle, Thierry Coche, Jamila Louahed

David D. Shersher, MD, Michael S

Gerald B. W. Wertheim, Catherine Smith, Maria E

Modified Real-Time PCR for Detecting, Differentiating, and Quantifying Ureaplasma urealyticum and Ureaplasma parvum Ellen Vancutsem, Oriane Soetens,

Amplification Patterns of Three Genomic Regions Predict Distant Recurrence in Breast Carcinoma Lisa M. Davis, Cole Harris, Lei Tang, Patti Doherty, Peter.

Diego M. Marzese, Dave S. B. Hoon, Kelly K. Chong, Francisco E

A Novel Approach to Detect Programed Death Ligand 1 (PD-L1) Status and Multiple Tumor Mutations Using a Single Non–Small-Cell Lung Cancer (NSCLC) Bronchoscopy.

Anu Aggarwal, Manu Jamwal, Ganesh K

Expression Of Human Chorionic Gonadotropin β-Subunit Type I Genes Predicts Adverse Outcome In Renal Cell Carcinoma Kristina Hotakainen, Susanna Lintula,

Quantification of Circulating miRNAs in Plasma

Association of MicroRNA Expression with Microsatellite Instability Status in Colorectal Adenocarcinoma Jonathan S.L. Earle, Rajyalakshmi Luthra, Angela.

Avoiding Pitfalls in Molecular Genetic Testing

Intratumoral Heterogeneity of MicroRNA Expression in Breast Cancer

Amplification and Overexpression of the EMS 1 Oncogene, a Possible Prognostic Marker, in Human Hepatocellular Carcinoma Bao-Zhu Yuan, Xiaoling Zhou,

MiRNA Profiling Identifies Candidate miRNAs for Bladder Cancer Diagnosis and Clinical Outcome Nadine Ratert, Hellmuth-Alexander Meyer, Monika Jung, Poline.

Custom Design of a GeXP Multiplexed Assay Used to Assess Expression Profiles of Inflammatory Gene Targets in Normal Colon, Polyp, and Tumor Tissue Janice.

Michael J. Germain, MD, Sara N. Davison, MD, Alvin H. Moss, MD

Abdominal aortic aneurysm anatomic severity grading score predicts implant-related complications, systemic complications, and mortality W. Burke Best,

Validation of Roche LightCycler Epstein-Barr Virus Quantification Reagents in a Clinical Laboratory Setting Margaret L. Gulley, Hongxin Fan, Sandra H.

Nathan D. Montgomery, Sara R. Selitsky, Nirali M. Patel, D

Improved Detection of the KIT D816V Mutation in Patients with Systemic Mastocytosis Using a Quantitative and Highly Sensitive Real-Time qPCR Assay Thomas.

Volume 23, Issue 11, Pages (November 2015)

Lauren J. Massingham, Kirby L. Johnson, Diana W

Measurement of Relative Copy Number of CDKN2A/ARF and CDKN2B in Bladder Cancer by Real-Time Quantitative PCR and Multiplex Ligation-Dependent Probe Amplification

Fig. 1. FAM83H over-expression is associated with poor prognosis of CC

Presentation transcript:

miR-210 Is a Prognostic Marker in Clear Cell Renal Cell Carcinoma Sara Samaan, Heba W.Z. Khella, Andrew Girgis, Andreas Scorilas, Evi Lianidou, Manal Gabril, Sergey N. Krylov, Michael Jewett, Georg A. Bjarnason, Hala El-said, George M. Yousef The Journal of Molecular Diagnostics Volume 17, Issue 2, Pages 136-144 (March 2015) DOI: 10.1016/j.jmoldx.2014.10.005 Copyright © 2015 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

Figure 1 Validated miR-210 overexpression and hypoxia-related genes in ccRCC compared with normal counterpart from the same patient. A: miR-210 expressions in 69 pairs of normal kidney and adjacent ccRCC tissues were compiled from The Cancer Genome Atlas. Cases are shown on the x axis and expression levels on the y axis. B: Average normal and cancer expression values of miR-210 and hypoxia-related genes in the same cases. Similar to the RT-qPCR findings, miR-210 expression is higher in cancer tissues relative to normal tissues, and a similar trend is seen in the expression of hypoxia-related genes. ccRCC, clear cell renal cell carcinoma; RT-qPCR, quantitative real-time RT-PCR. The Journal of Molecular Diagnostics 2015 17, 136-144DOI: (10.1016/j.jmoldx.2014.10.005) Copyright © 2015 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

Figure 2 Kaplan-Meier curves for DFS and OS of patients with miR-210+ and miR-210− tumors. miR-210+ patients have significantly lower DFS (A) and lower OS (B) compared with miR-210− patients. DFS, disease-free survival; OS, overall survival. The Journal of Molecular Diagnostics 2015 17, 136-144DOI: (10.1016/j.jmoldx.2014.10.005) Copyright © 2015 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

Figure 3 Kaplan-Meier curves for DFS and OS of patients within subgroup of tumors >4 cm. Within this subgroup, miR-210+ patients had lower DFS (A) and lower OS (B) than miR-210− patients. DFS, disease-free survival; OS, overall survival. The Journal of Molecular Diagnostics 2015 17, 136-144DOI: (10.1016/j.jmoldx.2014.10.005) Copyright © 2015 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

Figure 4 The correlation between miR-210 expression and tumor grade and stage. Cases are shown on the x axis and expression levels are on the y axis. miR-210 expression is not significantly associated with pathologic stage (A) and tumor size (B) in ccRCC patients. C: Kaplan-Meier survival curve shows that miR-210+ patents have statistically lower overall survival compared with miR-201− patients (P = 0.0257). The horizontal line in the middle of each box indicates the median, and the top and bottom borders of the box mark the 75th and 25th percentiles, respectively. The whiskers above and below the box mark the 90th and 10th percentiles. ccRCC, clear cell renal cell carcinoma. The Journal of Molecular Diagnostics 2015 17, 136-144DOI: (10.1016/j.jmoldx.2014.10.005) Copyright © 2015 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

Figure 5 miR-210 expression in different subtypes of renal cell carcinoma and oncocytoma. miR-210 expression was quantified by RT-qPCR analysis. Average miR-210 expression is depicted for each subtype. miR-210 is most up-regulated in clear cell renal carcinoma compared with the other subtypes. RT-qPCR, quantitative real-time RT-PCR. The Journal of Molecular Diagnostics 2015 17, 136-144DOI: (10.1016/j.jmoldx.2014.10.005) Copyright © 2015 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions